Form 4: InspireMD Director's Controlled Entity Boosts Stake with Share and Warrant Acquisition

An entity controlled by InspireMD Director Paul Stuka acquired 87,500 common shares and warrants, increasing his reported beneficial ownership in the company.

Summary

• InspireMD, Inc. Director Paul Stuka reported changes in his beneficial ownership via a Form 4 filing.
• Osiris Investment Partners, L.P., an entity where Mr. Stuka serves as managing member of its general partner, acquired 87,500 shares of InspireMD Common Stock at a price of $1.3827 per share.
• This acquisition, dated July 1, 2025, was made pursuant to a Rule 10b5-1 plan.
• Osiris also acquired 87,500 Series I Warrants with an exercise price of $1.3827, exercisable from May 15, 2023, and expiring on July 23, 2025.
• Following these transactions, Mr. Stuka's indirect beneficial ownership through Osiris stands at 423,534 shares.
• His direct beneficial ownership is reported as 360,284 shares.
• Mr. Stuka disclaims beneficial ownership of the indirectly held securities except to the extent of his pecuniary interest, noting that he did not directly effect these transactions but is reporting them due to deemed beneficial ownership.

Sentiment

Score: 7

Explanation: The acquisition of shares and warrants by an entity controlled by a director, even if indirect and under a 10b5-1 plan, generally signals insider confidence and aligns management interests with shareholders, indicating a positive outlook despite the disclaimer of direct transaction by the reporting person.

Positives

• An entity controlled by Director Paul Stuka acquired 87,500 common shares and 87,500 warrants, signaling confidence in InspireMD's future prospects.
• The acquisition was made under a Rule 10b5-1 plan, indicating a pre-planned investment strategy.

Negatives

• The filing indicates the transaction was not directly effected by the reporting person (Paul Stuka) but by an entity he controls, which slightly lessens the direct insider buying signal.
• The transaction date of July 1, 2025, is in the future, which might indicate a forward-looking plan rather than an immediate market transaction.

Risks

• The reporting person disclaims beneficial ownership of the indirectly held securities except to the extent of his pecuniary interest, which could imply limited personal financial exposure or control over these specific shares.

Future Outlook

The acquisition date of July 1, 2025, suggests a forward-looking investment plan, potentially indicating management's long-term confidence in the company's trajectory.

Management Comments

• The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.
• No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

Industry Context

Insider buying, even if indirect and under a 10b5-1 plan, generally signals management's belief in the company's undervaluation or strong future prospects, which can be a positive indicator for investors in the medical device industry where long-term development and regulatory milestones are key.

Comparison to Industry Standards

• Insider transactions are common across all industries. The acquisition of shares by a director, even indirectly, is generally viewed as a positive signal of confidence, aligning management's interests with shareholders.
• The use of a Rule 10b5-1 plan is a standard practice for insiders to trade company stock in a pre-arranged manner, mitigating concerns about trading on material non-public information.
• The specific value of the transaction ($1.3827 per share) would need to be compared against NSPR's historical stock performance and analyst price targets to assess its significance relative to industry peers like Medtronic (MDT) or Boston Scientific (BSX), but this filing does not provide enough context for such a detailed comparison.

Related Party Transactions

• The acquisition of securities was made by Osiris Investment Partners, L.P., an entity where the reporting person, Paul Stuka, serves as the managing member of its general partner, Osiris Partners, LLC. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The increase in beneficial ownership by a director's controlled entity may be viewed positively, signaling confidence and potentially bolstering investor sentiment.
• Management: The transaction aligns the financial interests of a key director more closely with the company's performance.

Next Steps

• The Series I Warrants can be exercised until July 23, 2025, potentially leading to further share acquisitions.

Key Dates

Recommendation

While the insider acquisition by a director's controlled entity is a positive signal of confidence, the future transaction date and the disclaimer that the reporting person did not directly effect the transaction temper the immediate bullishness. Investors should hold and monitor future developments and the company's operational performance for stronger buy signals.

Keywords

InspireMD, NSPR, Paul Stuka, Director, Insider Trading, Form 4, Beneficial Ownership, Stock Acquisition, Warrants, Rule 10b5-1, Osiris Investment Partners